Local hormone therapy for genitourinary syndrome of menopause in breast cancer patients: is it safe?

about

A medical device containing purified bovine colostrum (Monurelle Biogel) in the treatment of vulvovaginal atrophy in postmenopausal women: Retrospective analysis of urinary symptoms, sexual function, and quality of life.Consequences of premature ovarian insufficiency on women's sexual health

P2860

Q47422709-B0641903-A837-4CF3-A1CC-B9FDCA7C87A1 Q57823057-B92BFBE2-01EE-4153-A957-985E849DEDC1

P2860

Local hormone therapy for genitourinary syndrome of menopause in breast cancer patients: is it safe?

Item

http://www.wikidata.org/entity/Q39170418

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Local hormone therapy for geni ...... t cancer patients: is it safe?

@en

Local hormone therapy for geni ...... t cancer patients: is it safe?

@nl

type

Item

label

Local hormone therapy for geni ...... t cancer patients: is it safe?

@en

Local hormone therapy for geni ...... t cancer patients: is it safe?

@nl

prefLabel

Local hormone therapy for geni ...... t cancer patients: is it safe?

@en

Local hormone therapy for geni ...... t cancer patients: is it safe?

@nl

P1476

Local hormone therapy for geni ...... t cancer patients: is it safe?

@en

P2093

María Fernanda Garrido Oyarzún

http://www.w3.org/2001/XMLSchema#string

P2860

The Recent Review of the Genitourinary Syndrome of Menopause

Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels.

Urogenital disorders associated with oestrogen deficiency: the role of promestriene as topical oestrogen therapy.

Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer.

Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue.

Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator.

Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy.

Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: is it safe even in cancer patients?

A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer.

Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.

P304

418-420

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/09513590.2017.1290076

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Camil Castelo-Branco

P577

2017-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28277141

http://www.w3.org/2001/XMLSchema#string

Local hormone therapy for genitourinary syndrome of menopause in breast cancer patients: is it safe?

about

P2860

P2860

Local hormone therapy for genitourinary syndrome of menopause in breast cancer patients: is it safe?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698